Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
- M Diago1,
- G Castellano2,
- J García-Samaniego3,
- C Pérez1,
- I Fernández2,
- M Romero3,
- O L Iacono4,
- C García-Monzón5
- 1Section of Hepatology, University General Hospital, Valencia, Spain
- 2Service of Gastroenterology, University Hospital Doce de Octubre, Madrid, Spain
- 3Service of Gastroenterology, Hospital Carlos III, Madrid, Spain
- 4Gastroenterology Department, University of Palermo, Italy
- 5Liver Research Unit, University Hospital Santa Cristina, Madrid, Spain
- Correspondence to:
Dr C García-Monzón
Liver Research Unit, University Hospital Santa Cristina, Maestro Vives, 2, 28009-Madrid, Spain;
- Accepted 16 August 2005
- Revised 8 August 2005
- Published Online First 8 September 2005
Background: Increased serum and intrahepatic interferon γ inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described.
Aim: To analyse the possible association of serum IP-10 levels with different outcomes to antiviral therapy.
Patients: A total of 137 CHC patients treated with peginterferon plus ribavirin.
Methods: Serum IP-10 levels were determined by enzyme linked immunosorbent assay before therapy, after 12 weeks of treatment, and 24 weeks after cessation of therapy. Variables significantly associated with a sustained virological response (SVR) on univariate analysis were included in a multivariate logistic regression model.
Results: Pretreatment serum IP-10 levels in patients with SVR were significantly lower than in non-responders (NR) (332.4 (222.1) v 476.8 (305.3) pg/ml, respectively; p = 0.004). Serum IP-10 concentrations significantly decreased in patients with SVR (pretreatment: 332.4 (222.1) pg/ml; post-treatment: 170.2 (140.1) pg/ml; p<0.001) but not in NR (pretreatment: 476.8 (305.3) pg/ml; post treatment: 387.3 (268.1) pg/ml; p = 0.06). By multivariate analysis, non-1 genotype (odds ratio (OR) 3.5 (95% confidence interval (CI) 1.1–10.4); p = 0.003) and low viral load at baseline (OR 0.34 (95% CI 0.14–0.79); p = 0.01) were independent predictors of SVR in all patients. When multivariate analysis was restricted to patients with genotype 1, only baseline viral load (OR 0.38 (95% CI 0.155–0.96); p = 0.04) and pretreatment serum IP-10 levels (OR 0.99 (95% CI 0.996–0.999); p = 0.03) were identified as predictive factors of SVR.
Conclusion: Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients.
- CHC, chronic hepatitis C
- IFN, interferon
- IP-10, interferon γ inducible protein 10
- HCV, hepatitis C virus
- HSC, hepatic stellate cells
- NR, non-responders
- SVR, sustained virological response
- IL, interleukin
- ALT, alanine aminotransferase
- HBsAg, hepatitis B surface antigen
- HIV, human immunodeficiency virus
- ELISA, enzyme linked immunosorbent assay
- ROC, receiver operating characteristic
- AUC, area under the curve
Published online first 8 September 2005
Conflict of interest: None declared.